세계 CAR-T 치료 시장 규모는 2034년까지 35.9%의 CAGR로 성장할 것으로 예상됩니다.
신흥 시장에서의 CAR-T 세포 치료 채택이 시장 성장을 주도:
선진국에 비해 신흥시장에서의 CAR-T 세포 치료의 보급은 다소 늦은 편입니다. 그 주요 이유는 CAR-T 세포 치료에 많은 비용이 소요되고, 필요한 인프라와 전문지식을 갖추기가 쉽지 않기 때문입니다. 그러나 향후 몇 년 동안 신흥국에서의 CAR-T 세포 치료제 보급에 기여할 수 있는 여러 변수가 나타날 수 있습니다. 인구 고령화, 도시화, 건강에 해로운 생활습관 등으로 인해 중국, 인도, 브라질 등 일부 신흥국에서는 암 발병률이 눈에 띄게 증가하고 있으며, 질병 부담 증가로 인해 CAR-T 세포 치료와 같은 첨단 암 치료제의 필요성이 점점 더 커지고 있습니다.
신흥국에서는 CAR-T 세포 치료제의 개발, 생산, 유통을 촉진하기 위해 바이오제약 기업들이 현지 기업 및 연구기관과 협력하고 파트너십을 맺고 있습니다. 이러한 파트너십은 행정적, 법적 문제를 해결하는 데 도움이 되며, 중국과 인도와 같은 신흥 시장에서는 CAR-T 세포 치료제의 연구와 승인을 촉진하기 위해 규제 프레임워크와 가이드라인이 마련되고 있어 투자와 도입이 증가할 수 있습니다.
2023년, 바이오 제약사들은 신흥 지역에서 CAR-T 세포 치료제의 보급을 촉진하기 위해 공동 연구와 전략적 투자를 활용하기 위한 노력을 강화했습니다. 다음은 2023년 주목할 만한 진전 및 사업 지출의 예시입니다.
노바티스는 2023년 초 싱가포르에 CAR-T 세포 치료제 생산시설을 건설할 계획을 발표했습니다. 이 공장은 중국, 인도 등 신흥국 시장을 포함한 아시아태평양에 대응할 예정입니다. 또한 중국 내 CAR-T 세포 치료제의 추가 연구 및 판매를 위해 광저우 바이오리셀테라피(Guangzhou Bio-Ree Cell Therapy Co., Ltd.)와의 제휴를 확대했습니다.
길리어드 사이언스(Gilead Sciences)와 인도 생명공학 기업 인도바이오사이언스(IndiaBioScience)가 2023년 3월 인도 시장용 CAR-T 세포 치료제 연구 및 생산을 위한 전략적 제휴를 맺었습니다. 이번 제휴는 길리어드의 CAR-T 세포 치료제 기술과 인도바이오사이언스의 세포 치료제 제조 경험을 활용하여 인도 환자들에게 이러한 의약품을 제공하는 것을 목표로 합니다.
세계 CAR-T 치료 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각 부문별·지역별·주요 국가별 상세 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 보고서 개요
제2장 주요 요약
제3장 시장 개요
주요 조사 결과
시장 역학
영향 분석
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
공급망 분석
규제 프레임워크
COVID-19의 영향 분석
Porter's Five Forces 분석
PEST 분석
제4장 CAR-T 치료 시장 분석 : 표적 항원별
주요 조사 결과
시장 매력도 지수
시장 규모 추정과 예측
CD19/CD22
BCMA
기타
시장 규모 추정과 예측 : 지역별
시장 점유율 : 지역별
제5장 CAR-T 치료 시장 분석 : 유형별
주요 조사 결과
시장 매력도 지수
시장 규모 추정과 예측
Abecma
Yescarta
Kymriah
Tecartus
기타
시장 규모 추정과 예측 : 지역별
시장 점유율 : 지역별
제6장 CAR-T 치료 시장 분석 : 적응증별
주요 조사 결과
시장 매력도 지수
시장 규모 추정과 예측
미만성대세포형 B세포 림프종(DLBCL)
급성 림프구성 백혈병(ALL)
여포성 림프종
다발성 골수종(MM)
기타
시장 규모 추정과 예측 : 지역별
시장 점유율 : 지역별
제7장 CAR-T 치료 시장 분석 : 최종사용자별
주요 조사 결과
시장 매력도 지수
시장 규모 추정과 예측
병원
전문 클리닉
기타
시장 규모 추정과 예측 : 지역별
시장 점유율 : 지역별
제8장 CAR-T 치료 시장 분석 : 환자별
주요 조사 결과
시장 매력도 지수
시장 규모 추정과 예측
소아
성인
고령자
시장 규모 추정과 예측 : 지역별
시장 점유율 : 지역별
제9장 CAR-T 치료 시장 분석 : 지역별
주요 조사 결과
시장 규모 추정과 예측
제10장 북미의 CAR-T 치료 시장 분석
제11장 유럽의 CAR-T 치료 시장 분석
제12장 아시아태평양의 CAR-T 치료 시장 분석
제13장 라틴아메리카의 CAR-T 치료 시장 분석
제14장 중동 및 아프리카의 CAR-T 치료 시장 분석
제15장 기업 개요
경쟁 상황
파이프라인 분석
전략적 전망
Gilead Sciences Inc.
Novartis AG
Bristol Myers Squibb
Johnson & Johnson Services, Inc.
AbbVie Inc.
Amgen Inc.
BioNTech S.E.
Bluebird bio, Inc.
Caribou Biosciences Inc.
GSK plc
CARsgen Therapeutics Holdings Limited
Pfizer Inc.
Autolus Therapeutics
Intellia Therapeutics
2seventy bio, Inc.
제16장 결론과 제안
Visiongain에 의한 결론
시장 진출 기업에 대한 제안
ksm
영문 목차
영문목차
The global CAR-T Therapy market is projected to grow at a CAGR of 35.9% by 2034
The CAR-T Therapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Adoption of CAR-T Cell Therapy in Emerging Markets Driving Market Growth
Compared to developed economies, the adoption of CAR-T cell therapy in emerging markets has been somewhat sluggish. This is mostly because these therapies come with hefty costs, and it cannot be easy to set up the required infrastructure and expertise. However, in the upcoming years, a number of variables may contribute to the growing use of CAR-T cell therapy in emerging countries. Aging populations, urbanization, and the adoption of unhealthy lifestyles are all contributing to a notable increase in cancer incidence in several emerging economies, including China, India, and Brazil. Advanced cancer therapies, such as CAR-T cell therapies, are becoming more and more necessary due to the growing burden of disease.
In emerging countries, biopharmaceutical companies are collaborating and forming partnerships with local companies and institutes to expedite the development, production, and distribution of CAR-T cell treatments. These partnerships can assist in resolving administrative and legal issues. In order to expedite the research and approval of CAR-T cell treatments, several emerging markets, like China and India, have put in place regulatory frameworks and guidelines. This could lead to increased investment and uptake.
Biopharmaceutical companies are stepping up their efforts in 2023 to leverage collaborations and strategic investments to boost the uptake of CAR-T cell treatments in emerging regions. The following are some noteworthy advancements and business expenditures in this field, particularly for 2023.
Novartis announced plans to build a production facility for CAR-T cell treatment in Singapore at the beginning of 2023. This plant will cater to the Asia-Pacific region, which includes developing markets such as China and India. To further research and market CAR-T cell therapies in China, the business increased its partnership with Guangzhou Bio-Ree Cell Therapy Co., Ltd.
Gilead Sciences and IndiaBioScience, an Indian biotechnology business, formed a strategic alliance in March 2023 to research and produce CAR-T cell treatments for the Indian market. The partnership intends to use Gilead's CAR-T cell therapy technology and IndiaBioScience's experience in cell therapy manufacturing to provide these medicines to patients in India.
In early 2023, Bristol Myers Squibb announced plans to open a CAR-T cell therapy production facility in China, working with regional businesses. Additionally, it has been claimed that the company is in talks to introduce its CAR-T cell therapies to regulatory bodies in Brazil and other Latin American countries.
Janssen announced in February 2023 that it will be extending its partnership with Nanjing Legend Biotech to include possible new targets and indications for the development and commercialization of CAR-T cell treatments in China. The business is also looking into joint ventures with regional businesses and organizations in other developing nations, such as Russia and India.
In early 2023, Poseida Therapeutics (China) reported encouraging preliminary results from its Phase 1 trial assessing P-BCMA-ALLO1, a candidate for allogeneic CAR-T cell treatment, in patients with relapsed or refractory multiple myeloma.
Chinese biopharmaceutical startup Cellular Biomedicine Group is developing autologous CAR-T cell treatment candidates for different cancer types in China, with hopes to start pivotal studies in 2023.
The investments above and collaborations underscore the increasing acknowledgment of the possibilities of CAR-T cell therapies in developing economies and the endeavours of biopharmaceutical corporations to get a foothold in these areas. Through creating manufacturing facilities, utilizing local expertise, and managing regulatory procedures, these firms seek to expand patients' access to these cutting-edge cancer medicines in developing economies.
What Questions Should You Ask before Buying a Market Research Report?
How is the CAR-T therapy market evolving?
What is driving and restraining the CAR-T therapy market?
How will each CAR-T therapy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each CAR-T therapy submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading CAR-T therapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
What are the CAR-T therapy projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of CAR-T therapy projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the CAR-T therapy market?
Where is the CAR-T therapy market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the CAR-T Therapy market today, and over the next 10 years:
Our 337-page report provides 117 tables and 192 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2034 and other analyses reveal commercial prospects
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CAR-T Therapy prices and recent developments.
Segments Covered in the Report
Indication
Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukaemia (ALL)
Follicular Lymphoma
Multiple Myeloma (MM)
Others
Type
Abecma
Yescarta
Kymriah
Tecartus
Others
Target Antigens
CD19/CD22
BCMA
Others
End-users
Hospitals
Specialty Clinics
Other End-users
Patient
Children
Adults
Seniors
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and U.S., China, Brazil, and Singapore leading national markets:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
Singapore
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
MEA
GCC
Israel
Rest of MEA
The report also includes profiles for some of the leading companies in the CAR-T Therapy Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies profiled in the report
2seventy bio, Inc.
AbbVie Inc.
Amgen Inc.
Autolus Therapeutics
BioNTech S.E.
Bluebird bio Inc.
Bristol-Myers Squibb
Caribou Biosciences, Inc.
CARsgen Therapeutics Holdings Limited
Gilead Sciences Inc.
GSK plc
Intellia Therapeutics
Johnson & Johnson Services, Inc.
Novartis AG
Pfizer Inc.
Overall world revenue for CAR-T Therapy Market, 2024 to 2034 in terms of value the market will surpass US$1,480 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the CAR-T Therapy Market, 2024 to 2034 report help you?
In summary, our 330+ page report provides you with the following knowledge:
Revenue forecasts to 2034 for CAR-T Therapy Market, 2024 to 2034, with forecasts for indication, type, target antigens, end-users and patient, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the CAR-T Therapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, Singapore, Japan, and Australia, among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for are Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson Services, Inc., AbbVie Inc., Amgen Inc., BioNTech S.E., Bluebird bio Inc., Caribou Biosciences, Inc., GSK plc, CARsgen Therapeutics Holdings Limited, Pfizer Inc., Autolus Therapeutics, Intellia Therapeutics, and 2seventy bio, Inc. of the major companies involved in the CAR-T Therapy Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the CAR-T Therapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to CAR-T Therapy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Increasing Cancer Incidence
3.3.1.2 Increasing Research and Development to Enhance Treatment with CAR-T Cell Therapy
3.3.1.3 Growing Ongoing Clinical Trials and Regulatory Approvals
3.3.2 Market Restraining Factors
3.3.2.1 High Cost of CAR-T Cell Therapy
3.3.2.2 Safety Concerns Remain a Critical Aspect Influencing the CAR-T Cell Therapy
3.3.3 Market Opportunities
3.3.3.1 Expanding Target Indications
3.3.3.2 Increasing Adoption of CAR-T Cell Therapy in Emerging Markets
3.4 Supply Chain Analysis
3.5 Regulatory Framework
3.6 COVID-19 Impact Analysis
3.7 Porter Analysis
3.8 PEST Analysis
3.8.1 Political Factors:
3.8.2 Economic Factors:
3.8.3 Social Factors:
3.8.4 Technological Factors:
4 CAR-T Therapy Market Analysis by Target Antigens
4.1 Key Findings
4.2 Target Antigens Segment: Market Attractiveness Index
4.3 CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
4.4 CD19/CD22
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 BCMA
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Others
4.6.1 Market Size by Region, 2024-2034 (US$ Million)
4.6.2 Market Share by Region, 2024 & 2034 (%)
5 CAR-T Therapy Market Analysis by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 CAR-T Therapy Market Size Estimation and Forecast by Type
5.4 Abecma
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Yescarta
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Kymriah
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Tecartus
5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Other Types
5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.8.2 Market Share by Region, 2024 & 2034 (%)
6 CAR-T Therapy Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.3 CAR-T Therapy Market Size Estimation and Forecast by Indication
6.4 Diffuse Large B-Cell Lymphoma (DLBCL)
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Acute Lymphoblastic Leukaemia (ALL)
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Follicular Lymphoma
6.6.1 Market Size by Region, 2024-2034 (US$ Million)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Multiple Myeloma (MM)
6.7.1 Market Size by Region, 2024-2034 (US$ Million)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Other Indication
6.8.1 Market Size by Region, 2024-2034 (US$ Million)
6.8.2 Market Share by Region, 2024 & 2034 (%)
7 CAR-T Therapy Market Analysis by End-users
7.1 Key Findings
7.2 End-users Segment: Market Attractiveness Index
7.3 CAR-T Therapy Market Size Estimation and Forecast by End-users
7.4 Hospitals
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Specialty Clinics
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Other End-users
7.6.1 Market Size by Region, 2024-2034 (US$ Million)
7.6.2 Market Share by Region, 2024 & 2034 (%)
8 CAR-T Therapy Market Analysis by Patient
8.1 Key Findings
8.2 Patient Segment: Market Attractiveness Index
8.3 CAR-T Therapy Market Size Estimation and Forecast by Patient
8.4 Children
8.4.1 Market Size by Region, 2024-2034 (US$ Million)
8.4.2 Market Share by Region, 2024 & 2034 (%)
8.5 Adults
8.5.1 Market Size by Region, 2024-2034 (US$ Million)
8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Seniors
8.6.1 Market Size by Region, 2024-2034 (US$ Million)
8.6.2 Market Share by Region, 2024 & 2034 (%)
9 CAR-T Therapy Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast
10 North America CAR-T Therapy Market Analysis
10.1 Key Findings
10.2 North America CAR-T Therapy Market Attractiveness Index
10.3 North America CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 North America CAR-T Therapy Market Size Estimation and Forecast by Country
10.5 North America CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
10.6 North America CAR-T Therapy Market Size Estimation and Forecast by Type
10.7 North America CAR-T Therapy Market Size Estimation and Forecast by Indication
10.8 North America CAR-T Therapy Market Size Estimation and Forecast by End-users
10.9 North America CAR-T Therapy Market Size Estimation and Forecast by Patients
10.10 U.S. CAR-T Therapy Market Analysis
10.11 Canada CAR-T Therapy Market Analysis
11 Europe CAR-T Therapy Market Analysis
11.1 Key Findings
11.2 Europe CAR-T Therapy Market Attractiveness Index
11.3 Europe CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Europe CAR-T Therapy Market Size Estimation and Forecast by Country
11.5 Europe CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
11.6 Europe CAR-T Therapy Market Size Estimation and Forecast by Type
11.7 Europe CAR-T Therapy Market Size Estimation and Forecast by Indication
11.8 Europe CAR-T Therapy Market Size Estimation and Forecast by End-users
11.9 Europe CAR-T Therapy Market Size Estimation and Forecast by Patients
11.10 Germany CAR-T Therapy Market Analysis
11.11 UK CAR-T Therapy Market Analysis
11.12 France CAR-T Therapy Market Analysis
11.13 Italy CAR-T Therapy Market Analysis
11.14 Spain CAR-T Therapy Market Analysis
11.15 Rest of Europe CAR-T Therapy Market Analysis
12 Asia Pacific CAR-T Therapy Market Analysis
12.1 Key Findings
12.2 Asia Pacific CAR-T Therapy Market Attractiveness Index
12.3 Asia Pacific CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Country
12.5 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
12.6 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Type
12.7 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Indication
12.8 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by End-users
12.9 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Patients
12.10 China CAR-T Therapy Market Analysis
12.11 Japan CAR-T Therapy Market Analysis
12.12 Singapore CAR-T Therapy Market Analysis
12.13 Australia CAR-T Therapy Market Analysis
12.14 South Korea CAR-T Therapy Market Analysis
12.15 Rest of Asia Pacific CAR-T Therapy Market Analysis
13 Latin America CAR-T Therapy Market Analysis
13.1 Key Findings
13.2 Latin America CAR-T Therapy Market Attractiveness Index
13.3 Latin America CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 Latin America CAR-T Therapy Market Size Estimation and Forecast by Country
13.5 Latin America CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
13.6 Latin America CAR-T Therapy Market Size Estimation and Forecast by Type
13.7 Latin America CAR-T Therapy Market Size Estimation and Forecast by Indication
13.8 Latin America CAR-T Therapy Market Size Estimation and Forecast by End-users
13.9 Latin America CAR-T Therapy Market Size Estimation and Forecast by Patients
13.10 Brazil CAR-T Therapy Market Analysis
13.11 Mexico CAR-T Therapy Market Analysis
13.12 Rest of Latin America CAR-T Therapy Market Analysis
14 MEA CAR-T Therapy Market Analysis
14.1 Key Findings
14.2 MEA CAR-T Therapy Market Attractiveness Index
14.3 MEA CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
14.4 MEA CAR-T Therapy Market Size Estimation and Forecast by Country
14.5 MEA CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
14.6 MEA CAR-T Therapy Market Size Estimation and Forecast by Type
14.7 MEA CAR-T Therapy Market Size Estimation and Forecast by Indication
14.8 MEA CAR-T Therapy Market Size Estimation and Forecast by End-users
14.9 MEA CAR-T Therapy Market Size Estimation and Forecast by Patients
